AFCAPS/TexCAPS Trial
< AFCAPS
(Redirected from Air Force Coronary Atherosclerosis Prevention Study)|
Low Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
AFCAPS/TexCAPS Trial On the Web |
|
American Roentgen Ray Society Images of AFCAPS/TexCAPS Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Click here to download slides for AFCAPS/TexCAPS.
Overview
Lovastatin 20-40 mg daily (in addition to low-saturated ad low-colesterol diet) reduced the incidence of first major acute cardiovascular event (MACE) during a follow-up of 5.2 years, in this study involving 5608 men and 997 women with average total cholesterol and LDL levels and low HDL levels[1].
References
- ↑ Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA; et al. (1998). "Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study". JAMA. 279 (20): 1615–22. PMID 9613910.